Table 1 Patient characteristics.
Characteristics | Nab-paclitaxel plus cisplatin (n = 127) | Gemcitabine plus cisplatin (n = 126) | P value |
|---|---|---|---|
Age (range) | 50 (22–69) | 52 (30–75) | 0.26 |
<40 | 26 (20.5) | 19 (15.0) | |
≥40 | 101 (79.5) | 107 (85.0) | |
ECOG performance status | |||
0 | 18 (14.2) | 22 (17.5) | 0.47 |
1 | 109 (85.8) | 104 (82.5) | |
Menopausal status | |||
Premenopausal | 61 (48.0) | 52 (40.9) | 0.28 |
Postmenopausal | 66 (52.0) | 74 (58.7) | |
Disease-free interval | |||
novo stage IV | 25 (19.7) | 23 (18.2) | 0.37 |
<1year | 11 (8.7) | 18 (14.3) | |
≥1year | 91 (71.7) | 85 (67.5) | |
Number of metastatic organ sites | |||
1 | 44 (34.6) | 50 (39.7) | 0.65 |
2 | 41 (32.3) | 40 (31.7) | |
≥3 | 42 (33.1) | 36 (28.6) | |
Metastatic sites | |||
Visceral disease | 86 (67.7) | 77 (61.1) | 0.27 |
Lung | 57 (44.9) | 56 (44.4) | 0.94 |
Liver | 34 (29.1) | 31 (24.6) | 0.69 |
Bone | 37 (29.1) | 34 (27.0) | 0.70 |
Lymph nodes | 87 (68.5) | 91 (72.2) | 0.52 |
Neoadjuvant or adjuvant chemotherapy | |||
Anthracycline | 86 (67.7) | 87 (69.0) | 0.82 |
Taxane | 86 (67.7) | 84 (66.7) | 0.85 |
Anthracycline and taxane | 75 (59.0) | 75 (59.5) | 0.93 |
Capecitabine | 2 (1.6) | 5 (4.0) | 0.44 |
